M V Bala
Overview
Explore the profile of M V Bala including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sollano J, Kirsch J, Bala M, Chambers M, Harpole L
Clin Pharmacol Ther
. 2008 Jun;
84(2):263-6.
PMID: 18547999
Although it is commonly believed that the innovation of new medicines is of paramount importance for improving the health and quality of life of patients, there is also a keen...
2.
Bala M, Mauskopf J
Int J Technol Assess Health Care
. 2001 May;
17(1):27-37.
PMID: 11329843
Current health economic literature does not provide clear guidelines on how uncertainty around cost-effectiveness estimates should be incorporated into economic decision models. Bayesian analysis is a promising alternative to classical...
3.
Feagan B, Vreeland M, Larson L, Bala M
Am J Gastroenterol
. 2000 Aug;
95(8):1955-60.
PMID: 10950042
Objective: The aim of this study was to estimate the annual cost of care of patients with Crohn's disease according to treatment setting. Methods: Using a 1994 integrated claims database,...
4.
Hauber A, Gnanasakthy A, Snyder E, Bala M, Richter A, Mauskopf J
Pharmacoeconomics
. 2000 Aug;
17(4):351-60.
PMID: 10947490
Objective: To estimate savings in the cost of caring for patients with Alzheimer's disease (AD) during 6 months, 1 year and 2 years of treatment with rivastigmine. An intermediate objective...
5.
Bala M, Zarkin G
Health Econ
. 2000 Mar;
9(2):177-80.
PMID: 10721019
In this paper, we examine the problems associated with using quality adjusted life years (QALYs) as the measure of effectiveness to evaluate interventions for acute conditions. We illustrate the way...
6.
Zarkin G, Cates S, Bala M
J Subst Abuse Treat
. 2000 Mar;
18(2):149-59.
PMID: 10716098
Previous economic studies of the benefits of drug treatment have limited their estimation to tangible benefits, and thus have underestimated the benefits of drug treatment. The willingness-to-pay (WTP) approach is...
7.
Cochrane M, Bala M, Downs K, Mauskopf J, Ben-Joseph R
Chest
. 2000 Feb;
117(2):542-50.
PMID: 10669701
Background: Patient compliance, inhalation devices, and inhalation techniques influence the effectiveness of inhaled medications. Methods: This article presents the results of a systematic literature review of studies measuring compliance with...
8.
Lincoff A, Mark D, Tcheng J, Califf R, Bala M, Anderson K, et al.
Circulation
. 2000 Jan;
102(24):2923-9.
PMID: 11113041
Background: In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade), abciximab administered with weight-adjusted heparin diminished the risk of ischemic complications within 30...
9.
Bala M, Wood L, Zarkin G, Norton E, Gafni A, OBrien B
J Clin Epidemiol
. 1999 Oct;
52(11):1047-53.
PMID: 10526998
The standard gamble method, as currently recommended for use in health care program evaluation, provides an individual's preference score or "utility weight" for living in a given health state for...
10.
Bala M, Mauskopf J, Wood L
Pharmacoeconomics
. 1999 May;
15(1):9-18.
PMID: 10345161
In this paper, we discuss the use of cost-benefit analysis (CBA) for evaluating new healthcare interventions, present the theoretical basis for the use of willingness to pay as a method...